Highlights Newsletter 1
This newsletter presents you the following key sessions:
2. The impact of COVID-19 on international lung cancer clinical trials
3. Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC
4. Frontline maintenance rucaparib and nivolumab in extensive stage small-cell lung cancer
5. Current status of lung cancer screening in Europe